Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Change in Accured Expenses (2022 - 2025)

CervoMed's Change in Accured Expenses history spans 9 years, with the latest figure at $454084.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses fell 58.38% year-over-year to $454084.0; the TTM value through Sep 2025 reached $1.1 million, up 0.91%, while the annual FY2024 figure was $690290.0, 46.45% down from the prior year.
  • Change in Accured Expenses for Q3 2025 was $454084.0 at CervoMed, down from $713608.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $1.1 million in Q3 2024 and bottomed at -$440808.0 in Q2 2022.
  • The 4-year median for Change in Accured Expenses is $203906.0 (2024), against an average of $205149.7.
  • The largest annual shift saw Change in Accured Expenses soared 1196.12% in 2023 before it plummeted 173.65% in 2024.
  • A 4-year view of Change in Accured Expenses shows it stood at $158332.0 in 2022, then soared by 272.64% to $590016.0 in 2023, then crashed by 65.44% to $203906.0 in 2024, then skyrocketed by 122.69% to $454084.0 in 2025.
  • Per Business Quant, the three most recent readings for CRVO's Change in Accured Expenses are $454084.0 (Q3 2025), $713608.0 (Q2 2025), and -$285439.0 (Q1 2025).